Mineralys CMO exercises options, sells shares

Mineralys Therapeutics, Inc. Chief Medical Officer David Malcom reported option exercises and related stock sales.

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. Chief Medical Officer David Malcom reported option exercises and related stock sales. On June 12, 2026, he exercised options for 6,349 shares of common stock at $1.08 per share and sold 6,349 shares in an open-market transaction at a weighted-average price of $23.9252 per share under a pre-arranged Rule 10b5-1 trading plan. On June 10, 2026, he exercised options for 2,170 shares at $16.00 per share and sold 2,170 shares at $25.00 per share. Following these transactions, Malcom directly holds 63,443 shares of Mineralys common stock.

Insider Trade Summary 10b5-1

Exercise and Sale: 8,519 shares ($165K approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Rodman David Malcom

Role Chief Medical Officer

Sold 8,519 shs ($206K)

Approx. gross sale proceeds $206K

Approx. exercise cost $42K

Approx. pre-tax spread $165K

Type	Security	Shares	Price	Value
Exercise	Stock Option	6,349	$0.00	$0.00
Exercise	Common Stock	6,349	$1.08	$7K
Sale	Common Stock	6,349	$23.9252	$152K
Exercise	Stock Option	2,170	$0.00	$0.00
Exercise	Common Stock	2,170	$16.00	$35K
Sale	Common Stock	2,170	$25.00	$54K

Holdings After Transaction: Stock Option — 23,714 contracts (Direct); Common Stock — 63,443 shares (Direct)

Footnotes (3)

1. F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
2. F2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $23.75 to $24.02. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
3. F3. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

Key Figures

Shares sold June 12, 2026: 6,349 shares Sale price June 12, 2026: $23.9252/share Shares sold June 10, 2026: 2,170 shares +5 more

8 metrics

Shares sold June 12, 2026 6,349 shares Common stock sold at weighted-average $23.9252 per share

Sale price June 12, 2026 $23.9252/share Weighted-average price across multiple open-market trades

Shares sold June 10, 2026 2,170 shares Common stock sold at $25.00 per share

Options exercised at $1.08 6,349 shares Common stock acquired via option exercise on June 12, 2026

Options exercised at $16.00 2,170 shares Common stock acquired via option exercise on June 10, 2026

Net shares sold 8,519 shares Total open-market sales across June 10 and June 12, 2026

Shares held after transactions 63,443 shares Direct common stock ownership following reported trades

Rule 10b5-1 plan adoption date October 6, 2025 Pre-arranged trading plan governing reported transactions

Key Terms

Rule 10b5-1 trading plan, weighted-average price, stock option, open-market sale, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted-average price financial

"The price reported in Column 4 is a weighted-average price."

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

stock option financial

"The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date..."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Mineralys Therapeutics (MLYS) report for David Malcom?

Mineralys Therapeutics reported that Chief Medical Officer David Malcom exercised stock options and sold common shares in open-market transactions. The filing shows paired option exercises and sales on June 10 and June 12, 2026, under a pre-arranged Rule 10b5-1 trading plan.

How many Mineralys Therapeutics (MLYS) shares did David Malcom sell?

David Malcom sold a total of 8,519 shares of Mineralys common stock. The transactions included 2,170 shares sold at $25.00 on June 10, 2026, and 6,349 shares sold at a weighted-average price of $23.9252 on June 12, 2026.

At what prices did David Malcom exercise Mineralys Therapeutics (MLYS) stock options?

Malcom exercised Mineralys stock options at strike prices of $1.08 and $16.00 per share. On June 12, 2026, he exercised 6,349 options at $1.08, and on June 10, 2026, he exercised 2,170 options at $16.00, converting options into common shares.

How many Mineralys Therapeutics (MLYS) shares does David Malcom hold after these transactions?

After the reported transactions, David Malcom directly holds 63,443 shares of Mineralys common stock. This figure reflects his position following the option exercises and related open-market sales disclosed in the June 10 and June 12, 2026 Form 4 filing.

Were David Malcom’s Mineralys Therapeutics (MLYS) share sales under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted on October 6, 2025. Such pre-arranged plans schedule trades in advance, providing structured, automatic selling independent of day-to-day market developments.

What do the weighted-average prices mean in the Mineralys Therapeutics (MLYS) Form 4?

The weighted-average prices reflect that Malcom’s June 12, 2026 sales occurred in multiple trades at prices between $23.75 and $24.02. The reported $23.9252 figure is the weighted-average, and detailed trade-by-trade pricing is available from the insider upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 06:04 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rodman David Malcom

(Last) (First) (Middle)

150 N. RADNOR CHESTER RD.

SUITE F200

(Street)

RADNOR PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/10/2026		M(1)		2,170	A	$16	65,613	D
Common Stock	06/10/2026		S(1)		2,170	D	$25	63,443	D
Common Stock	06/12/2026		M(1)		6,349	A	$1.08	69,792	D
Common Stock	06/12/2026		S(1)		6,349	D	$23.9252(2)	63,443	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$16	06/10/2026		M(1)			2,170	(3)	02/09/2033	Common Stock	2,170	$0	17,365	D
Stock Option	$1.08	06/12/2026		M(1)			6,349	(3)	07/11/2032	Common Stock	6,349	$0	6,349	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

2. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $23.75 to $24.02. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

3. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

Remarks:

	/s/ Adam Levy, Attorney-in-fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)